EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ResMed's Enterprise Value is $28,359 Mil.
ResMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,215 Mil. Therefore, ResMed's EV-to-EBIT for today is 23.34.
The historical rank and industry rank for ResMed's EV-to-EBIT or its related term are showing as below:
RMD'
s EV-to-EBIT Range Over the Past 10 Years
Min: 13.57 Med: 25.92 Max: 48.08
Current: 23.34
During the past 13 years, the highest EV-to-EBIT of ResMed was 48.08. The lowest was 13.57. And the median was 25.92.
RMD's EV-to-EBIT is ranked worse than 58.8% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 19.7
vs RMD: 23.34
The historical data trend for ResMed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ResMed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ResMed's EV-to-EBIT falls into.
ResMed's current Enterprise Value is $28,359 Mil.
ResMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,215 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (NYSE:RMD) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ResMed's Enterprise Value for the quarter that ended in Dec. 2023 was $26,483 Mil.
ResMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,215 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of ResMed's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RMD has been successfully added to your 